Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer

Isamu Okamoto, Eiji Moriyama, Shinji Fujii, Hiroto Kishi, Masanobu Nomura, Eisuke Goto, Chikage Kiyofuji, Fumiya Imamura, Takashi Mori, Mitsuhiro Matsumoto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: More than 30% of cases of non-small cell lung cancer (NSCLC) arise in patients aged ≥ 70 years. The efficacy and safety of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial. Methods: Twenty-five patients aged ≥ 70 years (median, 76; range, 70-83) with chemotherapy-naïve advanced NSCLC were enrolled between January 2001 and July 2003. Additional criteria included the presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients received carboplatin at an area under the curve of 5 mg/ml/min and paclitaxel at 180 mg/m 2 on the first day of consecutive 3 week periods. Results: The patients included four with stage IIIB, 19 with stage IV and two with recurrent disease. The median number of treatment cycles was three (range, 1-4). One complete response and six partial responses, yielding an objective response rate of 28%, were obtained. The median survival time was 12.3 months and the 1-year survival rate was 52%. Hematological toxicities of grade 3 or 4 included leukopenia (40%), neutropenia (68%) and anemia (4%). Non-hematological toxicities of grade 3 included arthralgia-myalgia (16%) and neuropathy (12%). The objective response rate for patients aged ≥ 75 years (n = 15) was 26%, and no evidence of excessive toxicity in these patients was apparent compared with those aged <75 years. Conclusion: The combination carboplatin-paclitaxel at these doses is a feasible treatment option with a favorable toxicity profile for fit elderly patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)188-194
Number of pages7
JournalJapanese journal of clinical oncology
Volume35
Issue number4
DOIs
Publication statusPublished - Apr 1 2005

Fingerprint

Carboplatin
Paclitaxel
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Myalgia
Leukopenia
Arthralgia
Neutropenia
Area Under Curve
Anemia
Survival Rate
Safety
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. / Okamoto, Isamu; Moriyama, Eiji; Fujii, Shinji; Kishi, Hiroto; Nomura, Masanobu; Goto, Eisuke; Kiyofuji, Chikage; Imamura, Fumiya; Mori, Takashi; Matsumoto, Mitsuhiro.

In: Japanese journal of clinical oncology, Vol. 35, No. 4, 01.04.2005, p. 188-194.

Research output: Contribution to journalArticle

Okamoto, I, Moriyama, E, Fujii, S, Kishi, H, Nomura, M, Goto, E, Kiyofuji, C, Imamura, F, Mori, T & Matsumoto, M 2005, 'Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer', Japanese journal of clinical oncology, vol. 35, no. 4, pp. 188-194. https://doi.org/10.1093/jjco/hyi059
Okamoto, Isamu ; Moriyama, Eiji ; Fujii, Shinji ; Kishi, Hiroto ; Nomura, Masanobu ; Goto, Eisuke ; Kiyofuji, Chikage ; Imamura, Fumiya ; Mori, Takashi ; Matsumoto, Mitsuhiro. / Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. In: Japanese journal of clinical oncology. 2005 ; Vol. 35, No. 4. pp. 188-194.
@article{922ece2a75a143cbb0a1f384fc6805f8,
title = "Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer",
abstract = "Background: More than 30{\%} of cases of non-small cell lung cancer (NSCLC) arise in patients aged ≥ 70 years. The efficacy and safety of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial. Methods: Twenty-five patients aged ≥ 70 years (median, 76; range, 70-83) with chemotherapy-na{\"i}ve advanced NSCLC were enrolled between January 2001 and July 2003. Additional criteria included the presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients received carboplatin at an area under the curve of 5 mg/ml/min and paclitaxel at 180 mg/m 2 on the first day of consecutive 3 week periods. Results: The patients included four with stage IIIB, 19 with stage IV and two with recurrent disease. The median number of treatment cycles was three (range, 1-4). One complete response and six partial responses, yielding an objective response rate of 28{\%}, were obtained. The median survival time was 12.3 months and the 1-year survival rate was 52{\%}. Hematological toxicities of grade 3 or 4 included leukopenia (40{\%}), neutropenia (68{\%}) and anemia (4{\%}). Non-hematological toxicities of grade 3 included arthralgia-myalgia (16{\%}) and neuropathy (12{\%}). The objective response rate for patients aged ≥ 75 years (n = 15) was 26{\%}, and no evidence of excessive toxicity in these patients was apparent compared with those aged <75 years. Conclusion: The combination carboplatin-paclitaxel at these doses is a feasible treatment option with a favorable toxicity profile for fit elderly patients with advanced NSCLC.",
author = "Isamu Okamoto and Eiji Moriyama and Shinji Fujii and Hiroto Kishi and Masanobu Nomura and Eisuke Goto and Chikage Kiyofuji and Fumiya Imamura and Takashi Mori and Mitsuhiro Matsumoto",
year = "2005",
month = "4",
day = "1",
doi = "10.1093/jjco/hyi059",
language = "English",
volume = "35",
pages = "188--194",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer

AU - Okamoto, Isamu

AU - Moriyama, Eiji

AU - Fujii, Shinji

AU - Kishi, Hiroto

AU - Nomura, Masanobu

AU - Goto, Eisuke

AU - Kiyofuji, Chikage

AU - Imamura, Fumiya

AU - Mori, Takashi

AU - Matsumoto, Mitsuhiro

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Background: More than 30% of cases of non-small cell lung cancer (NSCLC) arise in patients aged ≥ 70 years. The efficacy and safety of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial. Methods: Twenty-five patients aged ≥ 70 years (median, 76; range, 70-83) with chemotherapy-naïve advanced NSCLC were enrolled between January 2001 and July 2003. Additional criteria included the presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients received carboplatin at an area under the curve of 5 mg/ml/min and paclitaxel at 180 mg/m 2 on the first day of consecutive 3 week periods. Results: The patients included four with stage IIIB, 19 with stage IV and two with recurrent disease. The median number of treatment cycles was three (range, 1-4). One complete response and six partial responses, yielding an objective response rate of 28%, were obtained. The median survival time was 12.3 months and the 1-year survival rate was 52%. Hematological toxicities of grade 3 or 4 included leukopenia (40%), neutropenia (68%) and anemia (4%). Non-hematological toxicities of grade 3 included arthralgia-myalgia (16%) and neuropathy (12%). The objective response rate for patients aged ≥ 75 years (n = 15) was 26%, and no evidence of excessive toxicity in these patients was apparent compared with those aged <75 years. Conclusion: The combination carboplatin-paclitaxel at these doses is a feasible treatment option with a favorable toxicity profile for fit elderly patients with advanced NSCLC.

AB - Background: More than 30% of cases of non-small cell lung cancer (NSCLC) arise in patients aged ≥ 70 years. The efficacy and safety of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial. Methods: Twenty-five patients aged ≥ 70 years (median, 76; range, 70-83) with chemotherapy-naïve advanced NSCLC were enrolled between January 2001 and July 2003. Additional criteria included the presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients received carboplatin at an area under the curve of 5 mg/ml/min and paclitaxel at 180 mg/m 2 on the first day of consecutive 3 week periods. Results: The patients included four with stage IIIB, 19 with stage IV and two with recurrent disease. The median number of treatment cycles was three (range, 1-4). One complete response and six partial responses, yielding an objective response rate of 28%, were obtained. The median survival time was 12.3 months and the 1-year survival rate was 52%. Hematological toxicities of grade 3 or 4 included leukopenia (40%), neutropenia (68%) and anemia (4%). Non-hematological toxicities of grade 3 included arthralgia-myalgia (16%) and neuropathy (12%). The objective response rate for patients aged ≥ 75 years (n = 15) was 26%, and no evidence of excessive toxicity in these patients was apparent compared with those aged <75 years. Conclusion: The combination carboplatin-paclitaxel at these doses is a feasible treatment option with a favorable toxicity profile for fit elderly patients with advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=20344406477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344406477&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyi059

DO - 10.1093/jjco/hyi059

M3 - Article

C2 - 15845567

AN - SCOPUS:20344406477

VL - 35

SP - 188

EP - 194

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

ER -